Dogs with Mitral Valve Insufficiency and Heart Failure
- Description: The cardiology section is participating in a multicenter clinical trial evaluating a medical therapy for congestive heart failure in dogs. To qualify for the study dogs must have been diagnosed with mitral valvular insufficiency and resultant heart failure (shortness of breath/cough with accompanying radiographic evidence of pulmonary edema). Only dogs which have received medical therapy for congestive heart failure for less than 7 days are eligible for enrollment. Patients will be seen by the NCSU cardiologists at the time of enrollment and again at 1 week, 1 month, 3 months, 6 months, 9 months, and 12 months.
- minimum body weight of 5.5 lbs
- radiographic evidence of pulmonary edema and cardiomegaly (Vertebral Heart Score > 10.5)
- left sided murmur consistent with acquired valvular heart disease, grade 3/6 or louder
- treatment for CHF no longer than 7 days prior to enrollment in the study
- The pet can receive furosemide and any other rescue drug for up to 7 pre-enrollment days. After enrollment, oral furosemide, study drug, control drug (a cardiac drug, not placebo) and digoxin and/or diltiazem to control heart rate in atrial fibrillation are the only cardiac drugs that can be used until heart failure recurs and the pet leaves the study.
- Financial incentive: The study will cover essentially all cardiac related medical costs (travel, office visits with an NCSU cardiologist, echocardiogram, ECG, radiographs, lab work, blood pressure, and study drug or control) for up to 1 year.
- Contact: NCSU Cardiology 919-513-6694
Page last updated September 04, 2013